Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Zilucoplan in Generalized Myasthenia Gravis
2019-001564-30Phase 3Completed
- Sponsor
- Ra Pharmaceuticals
- Start
- Oct 2019
- Modality
- Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Zilucoplan with Placebo (2 arms). Primary endpoint: Change from Baseline in Myasthenia score at Week 12. Started Oct 2019; status: completed.
02
Drugs
zilucoplan
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on 2019-001564-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001564-30.